An Electronic Dashboard to Improve Dosing of Hydroxychloroquine Within the Veterans Health Care System: Time Series Analysis.

Veterans Health Administration audit and feedback dashboard electronic health record health IT hydroxychloroquine medical informatics patient safety

Journal

JMIR medical informatics
ISSN: 2291-9694
Titre abrégé: JMIR Med Inform
Pays: Canada
ID NLM: 101645109

Informations de publication

Date de publication:
12 May 2023
Historique:
received: 21 11 2022
accepted: 19 03 2023
revised: 03 02 2023
medline: 12 5 2023
pubmed: 12 5 2023
entrez: 12 5 2023
Statut: epublish

Résumé

Hydroxychloroquine (HCQ) is commonly used for patients with autoimmune conditions. Long-term use of HCQ can cause retinal toxicity, but this risk can be reduced if high doses are avoided. We developed and piloted an electronic health record-based dashboard to improve the safe prescribing of HCQ within the Veterans Health Administration (VHA). We observed pilot facilities over a 1-year period to determine whether they were able to improve the proportion of patients receiving inappropriate doses of HCQ. Patients receiving HCQ were identified from the VHA corporate data warehouse. Using PowerBI (Microsoft Corp), we constructed a dashboard to display patient identifiers and the most recent HCQ dose and weight (flagged if ≥5.2 mg/kg/day). Six VHA pilot facilities were enlisted to test the dashboard and invited to participate in monthly webinars. We performed an interrupted time series analysis using synthetic controls to assess changes in the proportion of patients receiving HCQ ≥5.2 mg/kg/day between October 2020 and November 2021. At the start of the study period, we identified 18,525 total users of HCQ nationwide at 128 facilities in the VHA, including 1365 patients at the 6 pilot facilities. Nationwide, at baseline, 19.8% (3671/18,525) of patients were receiving high doses of HCQ. We observed significant improvements in the proportion of HCQ prescribed at doses ≥5.2 mg/kg/day among pilot facilities after the dashboard was deployed (-0.06; 95% CI -0.08 to -0.04). The difference in the postintervention linear trend for pilot versus synthetic controls was also significant (-0.06; 95% CI -0.08 to -0.05). The use of an electronic health record-based dashboard reduced the proportion of patients receiving higher than recommended doses of HCQ and significantly improved performance at 6 VHA facilities. National roll-out of the dashboard will enable further improvements in the safe prescribing of HCQ.

Sections du résumé

BACKGROUND BACKGROUND
Hydroxychloroquine (HCQ) is commonly used for patients with autoimmune conditions. Long-term use of HCQ can cause retinal toxicity, but this risk can be reduced if high doses are avoided.
OBJECTIVE OBJECTIVE
We developed and piloted an electronic health record-based dashboard to improve the safe prescribing of HCQ within the Veterans Health Administration (VHA). We observed pilot facilities over a 1-year period to determine whether they were able to improve the proportion of patients receiving inappropriate doses of HCQ.
METHODS METHODS
Patients receiving HCQ were identified from the VHA corporate data warehouse. Using PowerBI (Microsoft Corp), we constructed a dashboard to display patient identifiers and the most recent HCQ dose and weight (flagged if ≥5.2 mg/kg/day). Six VHA pilot facilities were enlisted to test the dashboard and invited to participate in monthly webinars. We performed an interrupted time series analysis using synthetic controls to assess changes in the proportion of patients receiving HCQ ≥5.2 mg/kg/day between October 2020 and November 2021.
RESULTS RESULTS
At the start of the study period, we identified 18,525 total users of HCQ nationwide at 128 facilities in the VHA, including 1365 patients at the 6 pilot facilities. Nationwide, at baseline, 19.8% (3671/18,525) of patients were receiving high doses of HCQ. We observed significant improvements in the proportion of HCQ prescribed at doses ≥5.2 mg/kg/day among pilot facilities after the dashboard was deployed (-0.06; 95% CI -0.08 to -0.04). The difference in the postintervention linear trend for pilot versus synthetic controls was also significant (-0.06; 95% CI -0.08 to -0.05).
CONCLUSIONS CONCLUSIONS
The use of an electronic health record-based dashboard reduced the proportion of patients receiving higher than recommended doses of HCQ and significantly improved performance at 6 VHA facilities. National roll-out of the dashboard will enable further improvements in the safe prescribing of HCQ.

Identifiants

pubmed: 37171858
pii: v11i1e44455
doi: 10.2196/44455
pmc: PMC10221491
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e44455

Informations de copyright

©Anna Montgomery, Gary Tarasovsky, Zara Izadi, Stephen Shiboski, Mary A Whooley, Jo Dana, Iziegbe Ehiorobo, Jennifer Barton, Lori Bennett, Lorinda Chung, Kimberly Reiter, Elizabeth Wahl, Meera Subash, Gabriela Schmajuk. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 12.05.2023.

Références

Expert Rev Clin Immunol. 2020 Jul;16(7):659-666
pubmed: 32620062
Ann Rheum Dis. 2022 Mar;81(3):370-378
pubmed: 34911705
Arthritis Rheumatol. 2021 Jun;73(6):908-911
pubmed: 33559327
J Am Pharm Assoc (2003). 2019 Mar - Apr;59(2S):S96-S103.e3
pubmed: 30713078
Appl Clin Inform. 2020 Jan;11(1):153-159
pubmed: 32102107
Am J Health Syst Pharm. 2019 Jul 18;76(15):1143-1149
pubmed: 31361870
JAMA Ophthalmol. 2014 Dec;132(12):1453-60
pubmed: 25275721
Lancet. 2012 Apr 7;379(9823):1310-9
pubmed: 22357106
JAMA. 2022 Oct 11;328(14):1458-1460
pubmed: 36112387
Clin Transl Med. 2013 May 10;2(1):10
pubmed: 23663660
J Med Syst. 2017 Nov 20;42(1):5
pubmed: 29159719
BMC Nephrol. 2020 Apr 16;21(1):136
pubmed: 32299383
Health Econ. 2016 Dec;25(12):1514-1528
pubmed: 26443693
JMIR Hum Factors. 2018 May 31;5(2):e22
pubmed: 29853440
Int J Med Inform. 2015 Feb;84(2):87-100
pubmed: 25453274
Ann Fam Med. 2011 Sep-Oct;9(5):398-405
pubmed: 21911758
Clin Ther. 2020 Apr;42(4):573-582
pubmed: 32222360
Rheumatol Int. 2017 Oct;37(10):1611-1618
pubmed: 28748425
Arthritis Care Res (Hoboken). 2022 Feb;74(2):219-228
pubmed: 32937026
Am J Manag Care. 2010 Dec;16(12 Suppl HIT):e311-9
pubmed: 21322301

Auteurs

Anna Montgomery (A)

San Francisco VA Medical Center, San Francisco, CA, United States.

Gary Tarasovsky (G)

San Francisco VA Medical Center, San Francisco, CA, United States.
University of California San Francisco, San Francisco, CA, United States.

Zara Izadi (Z)

University of California San Francisco, San Francisco, CA, United States.

Stephen Shiboski (S)

University of California San Francisco, San Francisco, CA, United States.

Mary A Whooley (MA)

San Francisco VA Medical Center, San Francisco, CA, United States.
University of California San Francisco, San Francisco, CA, United States.
UCSF Philip R Lee Institute for Health Policy Studies, San Francisco, CA, United States.

Jo Dana (J)

San Francisco VA Medical Center, San Francisco, CA, United States.

Iziegbe Ehiorobo (I)

University of California San Francisco, San Francisco, CA, United States.

Jennifer Barton (J)

VA Portland Health Care System, Portland, OR, United States.

Lori Bennett (L)

Ralph H Johnson VA Medical Center, Charleston, SC, United States.

Lorinda Chung (L)

Palo Alto VA Medical Center, Palo Alto, CA, United States.
Stanford University, Palo Alto, CA, United States.

Kimberly Reiter (K)

Raymond G Murphy VA Medical Center, Albuquerque, AZ, United States.
University of New Mexico School of Medicine, Albuquerque, AZ, United States.

Elizabeth Wahl (E)

Seattle/Puget Sound VA Healthcare System, Seattle, WA, United States.

Meera Subash (M)

UT Physicians Center for Autoimmunity, Houston, TX, United States.

Gabriela Schmajuk (G)

San Francisco VA Medical Center, San Francisco, CA, United States.
University of California San Francisco, San Francisco, CA, United States.
UCSF Philip R Lee Institute for Health Policy Studies, San Francisco, CA, United States.

Classifications MeSH